ArticleNature communications2017
Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 86 citations in OpenAlex.
- Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026Article
- Article
- A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adults.medRxiv : the preprint server for health sciences · 2026Article
- Recent advances in HIV-1 envelope-based vaccine designs for guiding broadly neutralizing antibody response.Journal of virology · 2026Review
- Prediction of HIV-1 sensitivity to broadly neutralizing antibodies using statistical distribution sampling (SDS) technology.BMC bioinformatics · 2026Article
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Framework-mediated binding of foreign and self-glycans by IGHV4-34 antibodies.Frontiers in immunology · 2026Review
- Convergent mutation trajectories convert functional self-tolerance in IGHV4-34 B cells to genetic tolerance encoded in the antibody.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Structural and genetic basis of HIV-1 envelope V2 apex recognition by rhesus broadly neutralizing antibodies.The Journal of experimental medicine · 2025Article
- An HIV-1 gp41 peptide-liposome vaccine elicits neutralizing epitope-targeted antibody responses in healthy individuals.medRxiv : the preprint server for health sciences · 2025Article
- Transient regulatory T cell manipulation is limited by anti-antibody responses in HIV-1 envelope immunized rhesus macaques.iScience · 2025Article
- Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques.Nature communications · 2024Article
- Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.Cell host & microbe · 2024Article
- A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope.Journal of virology · 2024Article
- Enhancement of Neutralization Responses through Sequential Immunization of Stable Env Trimers Based on Consensus Sequences from Select Time Points by Mimicking Natural Infection.International journal of molecular sciences · 2023Article
- Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions.Cell reports. Medicine · 2023Article
- Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.Nature reviews. Immunology · 2023Review
- HIV-1 Vpu restricts Fc-mediated effector functions in vivo.Cell reports · 2022Article
- Self-assembling peptide nanofiber HIV vaccine elicits robust vaccine-induced antibody functions and modulates Fc glycosylation.Science advances · 2022Article
- Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1.NPJ vaccines · 2022Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
44 authors at 7 institutions in 3 countries.
Wilton B WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Jinsong ZhangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0002-2195-2997
Chuancang JiangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Nathan I NicelyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.ORCID http://orcid.org/0000-0002-0025-2377
Daniela FeraBoston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Kan LuoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Hua-Xin LiaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Thomas B KeplerBoston University School of Medicine, Boston, MA, 02118, USA.
Akshaya RameshBoston University School of Medicine, Boston, MA, 02118, USA.
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
James A HollandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Todd BradleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Nathan VandergriftDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Robert ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Andrew FoulgerDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Shi-Mao XiaDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Mark LouderVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, 20892, USA.ORCID http://orcid.org/0000-0001-7540-9263
Amanda EatonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Sampa SantraBoston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Richard ScearceDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Laura SutherlandDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Amanda NewmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Hilary Bouton-VervilleDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Cindy BowmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Howard BomzeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Feng GaoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Dawn J MarshallDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
John F WhitesidesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Xiaoyan NieDepartment of Immunology, Duke University, Durham, NC, 27710, USA.
Garnett KelsoeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Steven G ReedInfectious Disease Research Institute, Seattle, WA, 98102, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA, 98102, USA.
Kim ClaryInfectious Disease Research Institute, Seattle, WA, 98102, USA.
Marguerite KoutsoukosGSK Vaccines, Rixensart, 1330, Belgium.
David FrancoGSK Vaccines, Rixensart, 1330, Belgium.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, 20892, USA.
Stephen C HarrisonBoston Children's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. Barton.haynes@dm.duke.edu.
Laurent VerkoczyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA. Laurent.verkoczy@dm.duke.edu.
Duke University · USBoston Children's Hospital · USInfectious Disease Research Institute · USBoston University · USGlaxoSmithKline (Belgium) · BENational Institute of Allergy and Infectious Diseases · USJinan University · CN
Funding
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F. · 2012 to 2018
$204.7MTranslational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7MHIV-1 vaccine-elicited antibodies target envelope glycansR01AI120801 · NIAID · DUKE UNIVERSITY · PI SAUNDERS, KEVIN O · 2015 to 2024
$7.5MMPER broadly neutralizing antibody knockin mice to study anti-HIV Bcell responsesR01AI087202 · NIAID · SAN DIEGO BIOMEDICAL RESEARCH INSTITUTE · PI VERKOCZY, LAURENT KARL · 2010 to 2022
$5.5MDissection of polyreactivity and neutralization activity of HIV-1 AbsR01AI118571 · NIAID · DUKE UNIVERSITY · PI PERFECT, JOHN R., VERKOCZY, LAURENT KARL · 2016 to 2020
$3.2MData commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598kNIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI087202NIAID NIH HHS R01 AI118571NIAID NIH HHS R01 AI120801NIAID NIH HHS UM1 AI100645NIH HHS S10 OD018164
Abstract
A strategy for HIV-1 vaccine development is to define envelope (Env) evolution of broadly neutralizing antibodies (bnAbs) in infection and to recreate those events by vaccination. Here, we report host tolerance mechanisms that limit the development of CD4-binding site (CD4bs), HCDR3-binder bnAbs via sequential HIV-1 Env vaccination. Vaccine-induced macaque CD4bs antibodies neutralize 7% of HIV-1 strains, recognize open Env trimers, and accumulate relatively modest somatic mutations. In naive CD4bs, unmutated common ancestor knock-in mice Env
Indexed as
AIDS VaccinesAnimalsAntibodies, NeutralizingBinding Sites, AntibodyB-LymphocytesCD4 AntigensCell LineageClonal Anergyenv Gene Products, Human Immunodeficiency VirusFemaleGene Knock-In TechniquesHIV-1HIV AntibodiesHumansImmune ToleranceImmunizationAIDS VaccinesAntibodies, NeutralizingCD4 Antigensenv Gene Products, Human Immunodeficiency VirusHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.